Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries

• Published in: BMC infectious diseases 2017-11, Vol.17 (Suppl 1), p.692-692, Article 692
• Main Authors: Nayagam, Shevanthi, Sicuri, Elisa, Lemoine, Maud, Easterbrook, Philippa, Conteh, Lesong, Hallett, Timothy B, Thursz, Mark
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; AIDS; Analysis; Antigens; Antiviral agents; Antiviral Agents - therapeutic use; Communicable diseases; Cost analysis; Cost-Benefit Analysis; Diagnosis; Diagnostic systems; Disease control; Economic aspects; Health care; Hepatitis; Hepatitis B; Hepatitis B - diagnosis; Hepatitis B - drug therapy; Hepatitis B - economics; Hepatitis vírica; Humans; Income; Infections; Infectious diseases; Liver; Malalties infeccioses; Public health; Review; Studies; Viral hepatitis; World Health Organization
• ISSN: 1471-2334; 1471-2334
• DOI: 10.1186/s12879-017-2778-x

Many people living with chronic HBV infection remain undiagnosed until later stages of disease. Increasing testing and treatment rates form part of the strategy to respond to the WHO goal of eliminating viral hepatitis as a public health threat by 2030. However, achieving these ambitious targets is dependent on finding effective and cost-effective methods of scale up strategies. The aim of this study was to undertake a narrative review of the literature on economic evaluations of testing and treatment for HBV infection, to help inform the development of the 2017 WHO Hepatitis Testing Guidelines. We undertook a focussed literature review for economic evaluations on testing for HBV accompanied by antiviral treatment. The search was carried out in Pubmed and included only articles published after 2000 and written in English. We narratively synthesise the results and discuss the key drivers of cost-effectiveness and their applicability to low and middle-income countries (LMICs). Nine published studies were included in this review, only one of which was performed in a low or middle-income setting in West Africa. Eight studies were performed in high-income settings, seven among high risk groups and one among the general population. The studies were heterogeneous in many respects including the population and testing strategy under consideration, model structure and baselines parameters, willingness to pay thresholds and outcome measures used. However, most studies found HBV testing and treatment to be cost-effective, even at low HBsAg prevalence levels. Currently economic evaluations of HBV testing and treatment strategies in LMICs is lacking, therefore limiting the ability to provide formal recommendations on the basis of cost-effectiveness alone. Further implementation research is needed in order to help guide national policy planning.